NRx Pharmaceuticals (NRXP) Earnings Analysis

NRx Pharmaceuticals (NRXP) next reports earnings on 2026-08-17, consensus EPS -0.09 USD. Last quarter (2026-05-15) it beat with EPS -0.04 USD vs -0.05 USD est (+20%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -3.49.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NRXP next report earnings?

Next earnings date2026-08-17
Consensus EPS estimate-0.09 USD
Revenue estimate0.00B

NRXP earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.04 USD-0.05 USD+20%Beat
2026-03-230.19 USD-0.09 USD+311.1%Beat
2025-11-14-0.18 USD-0.11 USD-63.6%Miss
2025-05-15-0.34 USD-0.3 USD-13.3%Miss
2025-03-14-0.3 USD-0.2 USD-50%Miss
2024-11-14-0.15 USD-0.81 USD+81.5%Beat
2024-08-14-0.75 USD-0.81 USD+7.4%Beat

Beat rate: 4/7 (57%) over reported quarters with consensus data.

NRXP valuation and analyst view

Trailing P/E-3.49
Trailing EPS-0.75919 USD
Price / book-10.48
Dividend yield0.00%
Market cap0.08B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is NRx Pharmaceuticals (NRXP)'s next earnings date?

NRx Pharmaceuticals is next scheduled to report on 2026-08-17, with a consensus EPS estimate of -0.09 USD and revenue estimate of 0.00B.

Did NRXP beat earnings last quarter?

In its 2026-05-15 report, NRXP posted EPS of -0.04 USD versus a -0.05 USD estimate — a beat of 20%.

What is NRXP's earnings track record?

Over the last 7 reported quarters with consensus data, NRXP beat estimates 4 times (57%).

What is NRXP's current P/E ratio and EPS?

NRXP trades at a trailing P/E of -3.49 on trailing EPS of -0.7591880829775467 USD.

What do analysts rate NRXP?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell).